Evidence map›Paper›PMID 40599507›Full record

ReviewCureus2025

The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.

Trevor Jones, Moshe Shalom, Anjalika Chalamgari, Justin Gold, Brolyn Zomalan, Saarang Patel, Vikas Munjal, Mohammad F Khan, Yuncong Mao, Julian L Gendreau and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Trevor JonesDepartment of Neurosurgery, University of California San Diego, San Diego, USA.
Moshe ShalomDepartment of Neurosurgery, Children's Hospital at Montefiore, Bronx, USA.
Anjalika ChalamgariDepartment of Surgery, University of Florida, Gainesville, USA.
Justin GoldDepartment of Medicine, Rowan University Cooper Medical School, Camden, USA.
Brolyn ZomalanDepartment of Neurosurgery, University of California San Diego, San Diego, USA.
Saarang PatelDepartment of Neurosurgery, Seton Hall University, South Orange, USA.
Vikas MunjalDepartment of Neurosurgery, Ohio State University College of Medicine, Columbus, USA.
Mohammad F KhanDepartment of Neurosurgery, Indiana University School of Medicine, Indianapolis, USA.
Yuncong MaoDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Julian L GendreauDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, USA.
Mickey E AbrahamDepartment of Neurosurgery, University of California San Diego, San Diego, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is still no cure for Alzheimer's disease (AD), which remains the leading cause of dementia in Western countries. Neuromodulation, the use of electrical or chemical interventions to modify neuronal excitability, has shown promise in treating several neurological conditions and has become a topic of interest in the context of AD. We aim to review clinical trials related to neuromodulation in AD. Analysis of current clinical trials was conducted using ClinicalTrials.gov. The search term used was "Alzheimer's disease," and results were filtered for studies that included neuromodulation. One hundred and eleven clinical trials were found, and 82 trials remained after exclusion. All trials utilized some form of neuromodulation device as the primary intervention, with transcranial magnetic stimulation and transcranial direct current stimulation as the most common modalities. Thirty-six (43.9%) trials were completed, 20 (24.3%) were not yet recruiting, 23 (28.0%) were actively recruiting, and three (3.7%) were enrolling by invitation. Of the completed trials, only 11 (30.6%) had associated results, and of those 11, eight (22.2% of completed trials, 72.7% of trials with results) were associated with published articles in a peer-reviewed journal. All but one of the eight trials displayed some form of improvement in their metric of choice. Although the number of trials with published results is limited, there appears to be positive evidence of the efficacy of neuromodulation in treating AD. The medical community must continue to emphasize the need for additional clinical trials in this area.

Indexed as

alzheimer’s diseaseclinical trialsneuromodulationtdcstms

Identifiers

PMID40599507
PMCPMC12209552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.